Murphy Capital Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$1.05M Buy
11,053
+1,138
+11% +$118K 0.15% 107
2022
Q1
$1.17M Buy
9,915
+697
+8% +$78.2K 0.14% 106
2021
Q4
$1.19M Sell
9,218
-284
-3% -$33.1K 0.13% 111
2021
Q3
$1.07M Buy
9,502
+227
+2% +$25.9K 0.13% 110
2021
Q2
$960K Buy
9,275
+45
+0.5% +$4.24K 0.11% 115
2021
Q1
$771K Buy
9,230
+175
+2% +$14.8K 0.1% 128
2020
Q4
$826K Buy
9,055
+95
+1% +$7.88K 0.11% 119
2020
Q3
$715K Buy
8,960
+90
+1% +$7.02K 0.1% 120
2020
Q2
$613K Buy
8,870
+65
+0.7% +$4.62K 0.1% 126
2020
Q1
$553K Hold
8,805
0.1% 128
2019
Q4
$684K Sell
8,805
-900
-9% -$70.3K 0.1% 137
2019
Q3
$711K Sell
9,705
-300
-3% -$21.1K 0.11% 134
2019
Q2
$616K Sell
10,005
-600
-6% -$36.3K 0.09% 145
2019
Q1
$676K Sell
10,605
-507
-5% -$28.9K 0.1% 142
2018
Q4
$567K Hold
11,112
0.1% 152
2018
Q3
$644K Sell
11,112
-900
-7% -$44K 0.09% 160
2018
Q2
$582K Hold
12,012
0.08% 165
2018
Q1
$558K Hold
12,012
0.08% 164
2017
Q4
$451K Sell
12,012
-75
-0.6% -$2.75K 0.06% 186
2017
Q3
$440K Sell
12,087
-825
-6% -$31.5K 0.06% 188
2017
Q2
$508K Sell
12,912
-900
-7% -$32.9K 0.07% 175
2017
Q1
$433K Hold
13,812
0.06% 198
2016
Q4
$431K Sell
13,812
-1,200
-8% -$38.9K 0.07% 193
2016
Q3
$603K Sell
15,012
-600
-4% -$22.6K 0.09% 177
2016
Q2
$518K Buy
15,612
+2,700
+21% +$92.4K 0.08% 193
2016
Q1
$379K Sell
12,912
-900
-7% -$24.8K 0.06% 212
2015
Q4
$363K Hold
13,812
0.06% 222
2015
Q3
$327K Hold
13,812
0.05% 230
2015
Q2
$327K Hold
13,812
0.05% 247
2015
Q1
$327K Sell
13,812
-6,000
-30% -$135K 0.05% 254
2014
Q4
$420K Sell
19,812
-1,800
-8% -$36.2K 0.06% 220
2014
Q3
$367K Hold
21,612
0.06% 243
2014
Q2
$309K Hold
21,612
0.05% 261
2014
Q1
$267K Hold
21,612
0.04% 284
2013
Q4
$236K Hold
21,612
0.04% 282
2013
Q3
$250K Hold
21,612
0.05% 268
2013
Q2
$242K Buy
+21,612
New +$256K 0.05% 254

Other funds holding EW

Murphy Capital Management's EW Position: Q2 2022 in Review

Murphy Capital Management increased its Edwards Lifesciences (EW) stake by 11% in Q2 2022, buying an estimated $118K and bringing the position to 11,053 shares worth $1.05M. The position accounts for 0.15% of the portfolio, ranked #107.

Murphy Capital Management first reported a position in EW in Q2 2013 and has held it in 37 quarters since. The position peaked at $1.19M in Q4 2021. 1,272 funds tracked by Wall St. Rank hold EW as of Q2 2022.

  • Murphy Capital Management held 11,053 shares of Edwards Lifesciences worth $1.05M as of Q2 2022.
  • Murphy Capital Management bought 1,138 Edwards Lifesciences shares in Q2 2022, an estimated $118K.
  • Edwards Lifesciences made up 0.15% of Murphy Capital Management's portfolio in Q2 2022, its #107 holding.
  • Murphy Capital Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 37 quarters since.
  • Murphy Capital Management's Edwards Lifesciences position peaked at $1.19M in Q4 2021.
  • 1,272 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2022.

Based on Murphy Capital Management's 13F filing for Q2 2022, filed 13 Jul 2022.